Search

Your search keyword '"Fowler, V G"' showing total 141 results
Start Over Author "Fowler, V G"

Refine your results

more »

more »

more »

more »
141 results on '"Fowler, V G"'

2. Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia

Author

Pettigrew, M. M., primary, Kwon, J., additional, Gent, J. F., additional, Kong, Y., additional, Wade, M., additional, Williams, D. J., additional, Creech, C. B., additional, Evans, S., additional, Pan, Q., additional, Walter, E. B., additional, Martin, J. M., additional, Gerber, J. S., additional, Newland, J. G., additional, Hofto, M. E., additional, Staat, M. A., additional, Fowler, V. G., additional, Chambers, H. F., additional, and Huskins, W. C., additional

Published
2022
Full Text
View/download PDF

11. Candida infective endocarditis

Author

Baddley, J. W., Benjamin, D. K., Jr., Patel, M., Miró, J., Athan, E., Barsic, B., Bouza, E., Clara, L., Elliott, T., Kanafani, Z., Klein, J., Lerakis, S., Levine, D., Spelman, D., Rubinstein, E., Tornos, P., Morris, A. J., Pappas, P., Fowler, V. G., Jr., Chu, V. H., and Cabell, C.

Published
2008
Full Text
View/download PDF

18. Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis

Author

Athan, E., Harris, O., Korman, T. M., Kotsanas, D., Jones, P., Reinbott, P., Ryan, S., Fortes, C. Q., Garcia, P., Jones, S. B., Barsic, B., Bukovski, S., Selton-Suty, C., Aissa, N., Doco-Lecompte, T., Delahaye, F., Vandenesch, F., Tattevin, P., Hoen, B., Plesiat, P., Giamarellou, H., Giannitsioti, E., Tarpatzi, E., Durante-Mangoni, E., Iossa, D., Orlando, S., Ursi, M. P., Pafundi, P. C., D' Amico, F., Bernardo, M., Cuccurullo, S., Dialetto, G., Covino, F. E., Manduca, S., Della Corte, A., De Feo, M., Tripodi, M. F., Baban, T., Kanafani, Z. A., Kanj, S. S., Sfeir, J., Yasmine, M., Morris, A., Murdoch, D. R., Premru, M. M., Lejko-Zupanc, T., Almela, M., Ambrosioni, J., Azqueta, M., Brunet, M., Cervera, C., De Lazzari, E., Falces, C., Fuster, D., Garcia-de-la-Maria, C., Garcia-Gonzalez, J., Gatell, J. M., Marco, F., Miro, J. M., Moreno, A., Ortiz, J., Ninot, S., Pare, J. C., Pericas, J. M., Quintana, E., Ramirez, J., Sandoval, E., Sitges, M., Tolosana, J. M., Vidal, B., Vila, J., Bouza, E., Rodriguez-Creixems, M., Ramallo, V., Bradley, S., Wray, D., Steed, L., Cantey, R., Peterson, G., Stancoven, A., Woods, C., Corey, G. R., Reller, L. B., Fowler, V. G., Chu, V. H., Messina, J. A., Park, L., Sharma-Kuinkel, B. K., Carugati, M., Munoz, P., Baloch, K., Dixon, C. C., Harding, T., Jones-Richmond, M., Pappas, P., Park, L. P., Redick, T., Stafford, J., Anstrom, K., Bayer, A. S., Cabell, C. H., Karchmer, A. W., Sexton, D. J., Wang, A., Chu, V., Durack, D. T., Eykyn, S., Moreillon, P., Olaison, L., Raoult, D., Rubinstein, E., Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Duke University Medical Center, University of Barcelona, Medical University of South Carolina [Charleston] (MUSC), American University of Beirut [Beyrouth] (AUB), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Université de Tsukuba = University of Tsukuba, Pericàs, J M, Messina, J A, Garcia-de-la-Mària, C, Park, L, Sharma-Kuinkel, B K, Marco, F, Wray, D, Kanafani, Z A, Carugati, M, Durante Mangoni, E, Tattevin, P, Chu, V H, Moreno, A, Fowler, V G, Miró, J M, De Feo, Marisa, Athan, E11, Harris, O11, Korman, Tm12, Kotsanas, D13, Jones, P14, Reinbott, P14, Ryan, S14, Fortes, Cq15, Garcia, P16, Jones, Sb16, Barsic, B17, Bukovski, S17, Selton-Suty, C18, Aissa, N18, Doco-Lecompte, T18, Delahaye, F19, Vandenesch, F19, Tattevin, P20, Hoen, B21, Plesiat, P21, Giamarellou, H22, Giannitsioti, E22, Tarpatzi, E22, Durante-Mangoni, E23, Iossa, D23, Orlando, S23, Ursi, Mp23, Pafundi, Pc23, D' Amico, F23, Bernardo, M23, Cuccurullo, S23, Dialetto, G23, Covino, Fe23, Manduca, S23, DELLA CORTE, Alessandro, De Feo, M23, Tripodi, Mf24, Baban, T25, Kanafani, Za25, Kanj, Ss25, Sfeir, J25, Yasmine, M25, Morris, A26, Murdoch, Dr27, Premru, Mm28, Lejko-Zupanc, T28, Almela, M29, Ambrosioni, J29, Azqueta, M29, Brunet, M29, Cervera, C29, De Lazzari, E29, Falces, C29, Fuster, D29, Garcia-de-la-Mària, C29, Garcia-Gonzalez, J29, Gatell, Jm29, Marco, F29, Miró, Jm29, Moreno, A29, Ortiz, J29, Ninot, S29, Paré, Jc29, Pericas, Jm29, Quintana, E29, Ramirez, J29, Sandoval, E29, Sitges, M29, Tolosana, Jm29, Vidal, B29, Vila, J29, Bouza, E30, Muñoz, P, Rodríguez-Créixems, M30, Ramallo, V30, Bradley, S31, Wray, D32, Steed, L32, Cantey, R32, Peterson, G33, Stancoven, A33, Woods, C34, Corey, Gr34, Reller, Lb34, Fowler VG, Jr34, Chu, Vh34, Baloch, K, Chu, Vh, Corey, Gr, Dixon, Cc, Fowler VG, Jr, Harding, T, Jones-Richmond, M, Pappas, P, Park, Lp, Redick, T, Stafford, J, Anstrom, K, Athan, E, Bayer, A, Cabell, Ch, Hoen, B, Karchmer, Aw, Miró, Jm, Murdoch, Dr, Sexton, Dj, Wang, A, Chu, V, Durack, Dt, Eykyn, S, Moreillon, P, Olaison, L, Raoult, D, Rubinstein, E, and Sexton, Dj.

Subjects
0301 basic medicine, Male, medicine.disease_cause, 0302 clinical medicine, 80 and over, Medicaments antibacterians, 030212 general & internal medicine, Endocarditi, Prospective Studies, Aged, 80 and over, Endocarditis, Bacterial, General Medicine, Middle Aged, Staphylococcal Infections, 3. Good health, Anti-Bacterial Agents, Fenotip, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Treatment Outcome, Phenotype, Staphylococcus aureus, Infective endocarditis, Staphylococcus aureu, Vancomycin, Genotype, Vancomycin MIC, Adult, Aged, Endocarditis, Bacterial, Female, Humans, Microbial Sensitivity Tests, Molecular Typing, Multiplex Polymerase Chain Reaction, Survival Analysis, Virulence Factors, beta-Lactams, medicine.drug, Microbiology (medical), 030106 microbiology, Biology, Staphylococcal infections, Article, Microbiology, 03 medical and health sciences, Minimum inhibitory concentration, medicine, Etest, Endocarditis Staphylococcus aureus, biochemical phenomena, metabolism, and nutrition, medicine.disease, Antibacterial agents, Methicillin Susceptible Staphylococcus Aureus
Abstract

Objectives: Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is >= 1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (> 1.5mg/L) phenotype.Methods: All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal beta-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (>= 1.5 mg/L) or low (

Published
2017

20. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the Internation

Author

Pericàs, J. M., Messina, J. A., Garcia-de-la-Mària, C., Park, L., Sharma-Kuinkel, B. K., Marco, F., Wray, D., Kanafani, Z. A., Carugati, M., Durante-Mangoni, E., Tattevin, P., Chu, V. H., Moreno, A., Fowler, V. G., Miró, J. M., International Collaboration on Endocarditis Microbiology Investigators, Athan, E., Pericàs, J. M., Messina, J. A., Garcia-de-la-Mària, C., Park, L., Sharma-Kuinkel, B. K., Marco, F., Wray, D., Kanafani, Z. A., Carugati, M., Durante-Mangoni, E., Tattevin, P., Chu, V. H., Moreno, A., Fowler, V. G., Miró, J. M., International Collaboration on Endocarditis Microbiology Investigators, and Athan, E.

Published
2017

21. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Author

Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, L., Cheng, A. C., Doi, Y., Fowler, V. G., Jr., Kaye, K. S., Leibovici, L., Lipman, J., Llewelyn, M. J., Munoz-Price, S., Paul, M., Peleg, A. Y., Rodriguez-Bano, J., Rogers, B. A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., Paterson, D. L., Harris, P. N. A., McNamara, J. F., Lye, D. C., Davis, J. S., Bernard, L., Cheng, A. C., Doi, Y., Fowler, V. G., Jr., Kaye, K. S., Leibovici, L., Lipman, J., Llewelyn, M. J., Munoz-Price, S., Paul, M., Peleg, A. Y., Rodriguez-Bano, J., Rogers, B. A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S. Y. C., Turnidge, J., Utili, R., Webb, S. A. R., and Paterson, D. L.

Abstract

Objectives: To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI). Methods: Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. Results: Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed. Conclusions: These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes. (C) 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Published
2017

23. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae

Author

Evans, S., Cober, E., Richter, S. S., Bonomo, R. A., van Duin, D., Perez, F., Kalayjian, R. C., Salata, R. A., Kaye, K. S., and Fowler, V. G.

Subjects
urologic and male genital diseases, bacterial infections and mycoses
Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an important healthcare-associated pathogen. We evaluated the impact of CRKP strain type and treatment on outcomes of patients with CRKP bacteriuria.

Published
2014
Full Text
View/download PDF

24. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study

Author

Chirouze, C., Alla, F., Fowler, V. G., Sexton, D. J., Corey, G. R., Chu, V. H., Wang, A., Erpelding, M-L., Durante-Mangoni, E., Fernández-Hidalgo, N., Giannitsioti, E., Hannan, M. M., Lejko-Zupanc, T., Miró, J. M., Muñoz, P., Murdoch, D. R., Tattevin, P., Tribouilloy, C., Hoen, B., Athan, E., Chirouze, C., Alla, F., Fowler, V. G., Sexton, D. J., Corey, G. R., Chu, V. H., Wang, A., Erpelding, M-L., Durante-Mangoni, E., Fernández-Hidalgo, N., Giannitsioti, E., Hannan, M. M., Lejko-Zupanc, T., Miró, J. M., Muñoz, P., Murdoch, D. R., Tattevin, P., Tribouilloy, C., Hoen, B., and Athan, E.

Abstract

BACKGROUND: The impact of early valve surgery (EVS) on the outcome of Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unresolved. The objective of this study was to evaluate the association between EVS, performed within the first 60 days of hospitalization, and outcome of SA PVIE within the International Collaboration on Endocarditis-Prospective Cohort Study. METHODS: Participants were enrolled between June 2000 and December 2006. Cox proportional hazards modeling that included surgery as a time-dependent covariate and propensity adjustment for likelihood to receive cardiac surgery was used to evaluate the impact of EVS and 1-year all-cause mortality on patients with definite left-sided S. aureus PVIE and no history of injection drug use. RESULTS: EVS was performed in 74 of the 168 (44.3%) patients. One-year mortality was significantly higher among patients with S. aureus PVIE than in patients with non-S. aureus PVIE (48.2% vs 32.9%; P = .003). Staphylococcus aureus PVIE patients who underwent EVS had a significantly lower 1-year mortality rate (33.8% vs 59.1%; P = .001). In multivariate, propensity-adjusted models, EVS was not associated with 1-year mortality (risk ratio, 0.67 [95% confidence interval, .39-1.15]; P = .15). CONCLUSIONS: In this prospective, multinational cohort of patients with S. aureus PVIE, EVS was not associated with reduced 1-year mortality. The decision to pursue EVS should be individualized for each patient, based upon infection-specific characteristics rather than solely upon the microbiology of the infection causing PVIE.

Published
2015

25. QUINUPRISTIN/DALFOPRISTIN IN THE MANAGEMENT OF STAPHYLOCOCCAL INFECTIONS IN CRITICALLY ILL PATIENTS FAILING OR UNABLE TO TOLERATE VANCOMYCIN

Author

Palmer, Scott M., Drew, R H., Perfect, J R., Fowler, V G., and Lavin, B S.

Subjects
Anti-infective agents -- Evaluation, Staphylococcal infections -- Drug therapy, Health, Drug therapy, Evaluation
Abstract

Scott M Palmer, MD, MHS(*); R H Drew, PharmD; J R Perfect, MD; V G Fowler, MD and B S Lavin, MD. Duke University Medical Center, Durham, NC and Aventis [...]

Published
2000

26. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition

Author

Benito, N., Miro, J. M., Lazzari, E., Cabell, C. H., Del Rio, A., Altclas, J., Commerford, P., Delahaye, F., Dragulescu, S., Helen Giamarellou, Habib, G., Kamarulzaman, A., Kumar, A. S., Nacinovich, F. M., Suter, F., Tribouilloy, C., Venugopal, K., Moreno, A., Fowler, V. G., AII - Amsterdam institute for Infection and Immunity, and Infectious diseases

Abstract

BACKGROUND: The clinical profile and outcome of nosocomial and non-nosocomial health care-associated native valve endocarditis are not well defined. OBJECTIVE: To compare the characteristics and outcomes of community-associated and nosocomial and non-nosocomial health care-associated native valve endocarditis. DESIGN: Prospective cohort study. SETTING: 61 hospitals in 28 countries. PATIENTS: Patients with definite native valve endocarditis and no history of injection drug use who were enrolled in the ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) from June 2000 to August 2005. MEASUREMENTS: Clinical and echocardiographic findings, microbiology, complications, and mortality. RESULTS: Health care-associated native valve endocarditis was present in 557 (34%) of 1622 patients (303 with nosocomial infection [54%] and 254 with non-nosocomial infection [46%]). Staphylococcus aureus was the most common cause of health care-associated infection (nosocomial, 47%; non-nosocomial, 42%; P = 0.30); a high proportion of patients had methicillin-resistant S. aureus (nosocomial, 57%; non-nosocomial, 41%; P = 0.014). Fewer patients with health care-associated native valve endocarditis had cardiac surgery (41% vs. 51% of community-associated cases; P

Published
2009

27. Staphylococcus aureus Bacteremia at 5 US Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections

Author

David, M. Z., primary, Daum, R. S., additional, Bayer, A. S., additional, Chambers, H. F., additional, Fowler, V. G., additional, Miller, L. G., additional, Ostrowsky, B., additional, Baesa, A., additional, Boyle-Vavra, S., additional, Eells, S. J., additional, Garcia-Houchins, S., additional, Gialanella, P., additional, Macias-Gil, R., additional, Rude, T. H., additional, Ruffin, F., additional, Sieth, J. J., additional, Volinski, J., additional, and Spellberg, B., additional

Published
2014
Full Text
View/download PDF

28. Antibacterial Resistance Leadership Group: Open for Business

Author

Chambers, H. F., primary, Bartlett, J. G., additional, Bonomo, R. A., additional, Chiou, C., additional, Cosgrove, S. E., additional, Cross, H. R., additional, Daum, R. S., additional, Downing, M., additional, Evans, S. R., additional, Knisely, J., additional, Kreiswirth, B. N., additional, Lautenbach, E., additional, Mickley, B. S., additional, Patel, R., additional, Pettigrew, M. M., additional, Rodvold, K. A., additional, Spellberg, B., additional, and Fowler, V. G., additional

Published
2014
Full Text
View/download PDF

36. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography

Author

Rasmussen, R. V., primary, Host, U., additional, Arpi, M., additional, Hassager, C., additional, Johansen, H. K., additional, Korup, E., additional, Schonheyder, H. C., additional, Berning, J., additional, Gill, S., additional, Rosenvinge, F. S., additional, Fowler, V. G., additional, Moller, J. E., additional, Skov, R. L., additional, Larsen, C. T., additional, Hansen, T. F., additional, Mard, S., additional, Smit, J., additional, Andersen, P. S., additional, and Bruun, N. E., additional

Published
2011
Full Text
View/download PDF

37. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia

Author

Lalani, T., primary, Boucher, H. W., additional, Cosgrove, S. E., additional, Fowler, V. G., additional, Kanafani, Z. A., additional, Vigliani, G. A., additional, Campion, M., additional, Abrutyn, E., additional, Levine, D. P., additional, Price, C. S., additional, Rehm, S. J., additional, Corey, G. R., additional, and Karchmer, A. W., additional

Published
2007
Full Text
View/download PDF

39. Use of Vancomycin or First-Generation Cephalosporins for the Treatment of Hemodialysis-Dependent Patients with Methicillin-Susceptible Staphylococcus aureus Bacteremia

Author

Stryjewski, M. E., primary, Szczech, L. A., additional, Benjamin, D. K., additional, Inrig, J. K., additional, Kanafani, Z. A., additional, Engemann, J. J., additional, Chu, V. H., additional, Joyce, M. J., additional, Reller, L. B., additional, Corey, G. R., additional, and Fowler, V. G., additional

Published
2007
Full Text
View/download PDF

42. Reply to Shah

Author

Chu, V. H., primary, Cabell, C. H., additional, Corey, G. R., additional, Miro, J. M., additional, Stryjewski, M. E., additional, Pappas, P., additional, Habib, G., additional, and Fowler, V. G., additional

Published
2005
Full Text
View/download PDF

50. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia.

Author

Rosen AB, Fowler VG Jr., Corey GR, Downs SM, Biddle AK, Li J, Jollis JG, Rosen, A B, Fowler, V G Jr, Corey, G R, Downs, S M, Biddle, A K, Li, J, and Jollis, J G

Abstract

Background: The appropriate duration of therapy for catheter-associated Staphylococcus aureus bacteremia is controversial. Conventional practice dictates that all patients receive prolonged courses of intravenous antibiotics. Some clinicians recommend abbreviated therapeutic courses, but an alternate approach involves prospectively identifying patients for whom abbreviated therapy is appropriate.Objective: To determine the cost-effectiveness of transesophageal echocardiography (TEE) in establishing duration of therapy for catheter-associated S. aureus bacteremia.Design: Cost-effectiveness analysis.Data Sources: MEDLINE search of literature; clinical data from patients with S. aureus bacteremia (n = 196) and patients with endocarditis (n = 60); and costs obtained from the study institution, regional home health agency, and national estimates of professional and technical fees.Target Population: Patients with catheter-associated S. aureus bacteremia on native heart valves without intravenous drug use or clinically apparent metastatic infection, immunosuppression, or indwelling prosthetic devices.Time Horizon: Patient lifetime.Perspective: Societal.Interventions: Antibiotic treatment based on TEE results compared with 2- or 4-week empirical therapy.Outcome Measures: Quality-adjusted life expectancy, costs, and incremental cost-effectiveness ratios.Results Of Base-case Analysis: Compared with empirical short-course therapy, the TEE strategy cost $4938 per quality-adjusted life-year (QALY) gained. The effectiveness of the TEE strategy and the effectiveness of the long-course strategy were sufficiently similar that the additional cost of empirical long-course therapy ($1,667,971 per QALY) was higher than that which society usually considers cost-effective.Results Of Sensitivity Analyses: In a four-way sensitivity analysis (endocarditis prevalence, TEE cost, short-course relapse rate, and TEE specificity), compared with empirical short-course therapy, the TEE strategy results ranged from cost savings to $155,624 per QALY.Conclusion: Within the limitations of existing empirical data, this study suggests that for patients with clinically uncomplicated catheter-associated S. aureus bacteremia, the use of TEE to determine therapy duration is a cost-effective alternative to 2- or 4-week empirical therapy. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results